Kiora Pharmaceuticals, Inc. (KPRX) Fair Value 2026

KPRX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-28, Kiora Pharmaceuticals, Inc. (KPRX) trades at $2.62. QOC: 4.5/10. Value Trap Risk: 46/100 (WARN). 0/13 models active.

Key Facts

Ticker
KPRX
Price
$2.62
Quality Score
4.5/10
Value Trap Risk
46/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give KPRX?

0 Intrinsic Value Models vs. Current Price ($2.62)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Kiora Pharmaceuticals, Inc. (KPRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Kiora Pharmaceuticals, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About KPRX?

0 of 13 models are currently active for KPRX. See which stocks rank higher →

How Does KPRX Rank in Biotechnology?

Among 625 Biotechnology stocks, KPRX ranks #462 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Kiora Pharmaceuticals, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating KPRX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is KPRX a Value Trap?

CirclFi's Value Trap algorithm assigns KPRX a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Kiora Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Kiora Pharmaceuticals, Inc.'s fundamental quality profile registers 4.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KPRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Kiora Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BCDABioCardia, Inc.QOC 4.5ELVNEnliven Therapeutics, Inc.QOC 4.5GRDXGridAI Technologies Corp.QOC 4.5ALLRAllarity Therapeutics, Inc.QOC 4.4MSLESatellos Bioscience Inc.QOC 4.5SGMTSagimet Biosciences Inc.QOC 4.4ANLAdlai Nortye Group Ltd.QOC 2.1RANIRani Therapeutics Holdings, Inc.QOC 6.0CADLCandel Therapeutics, Inc.QOC 5.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BCDA · ELVN · GRDX · ALLR · MSLE · SGMT · ANL · RANI · CADL · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KPRX?

6 companies across all industries closest to KPRX’s Quality of Company score of 4.5/10.

FUSTFuse Group Holding Inc.QOC 4.5LRDCLaredo Oil, Inc.QOC 4.5ENRTEnertopia Corp.QOC 4.5PWCMPowerCompute, Inc.QOC 4.5RAKRRainmaker Worldwide Inc.QOC 4.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FUST · LRDC · ENRT · PWCM · RAKR · NVDA

Where Does KPRX Sit in CirclFi's Biotechnology Rankings?

KPRX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Kiora Pharmaceuticals, Inc.’s Valuation?

What is Kiora Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Kiora Pharmaceuticals, Inc. (KPRX). The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KPRX overvalued or undervalued right now?

At $2.62, 0 of 0 active models suggest KPRX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Kiora Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.5 mean for KPRX?

Kiora Pharmaceuticals, Inc.'s QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on KPRX?

CirclFi analyzes KPRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is KPRX a value trap in 2026?

Kiora Pharmaceuticals, Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Kiora Pharmaceuticals, Inc. (KPRX) a Quality of Company score of 4.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/KPRX/ · Methodology
Primary sources for this KPRX valuation
  • Financial statements: Kiora Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001372514) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KPRX as of ; valuations recomputed .